Dec. 23, 2021 — The antiviral remdesivir, an intravenous drug given principally to significantly unwell COVID-19 sufferers in hospitals, might hold unvaccinated individuals who turn out to be contaminated out of the hospital if given on an outpatient foundation, a brand new research says.

Researchers studied 562 unvaccinated individuals from September 2020 to April 2021, in response to the research revealed within the New England Journal of Medication. The research decided the chance of hospitalization or dying was 87% decrease in research members who got remdesivir than members who acquired a placebo.

All members had been at excessive threat of growing extreme COVID-19 due to their age — they had been over 60 — or as a result of they’d an underlying medical situation corresponding to diabetes or obesity.

An necessary caveat: The findings are primarily based on information collected earlier than the Delta variant surged final summer season or the Omicron variant surged late this 12 months, The Washington Put up reported.

The brand new research says the drug may very well be useful in preserving vaccinated in addition to unvaccinated individuals out of the hospital — an necessary issue because the Omicron surge threatens to overwhelm well being methods world wide.

Remdesivir may very well be a boon for COVID-19 sufferers in components of the world that don’t have vaccines or for sufferers with immunocompromised methods.

“These information present proof {that a} 3-day course of remdesivir might play a essential function in serving to COVID-19 sufferers keep out of the hospital,” Robert L. Gottlieb, MD, PhD, the therapeutic lead for COVID-19 analysis at Baylor Scott & White Well being in Dallas, mentioned in a information launch from Gilead Prescribed drugs.

“Whereas our hospitals are prepared to help sufferers in want, prevention and early intervention are preferable to cut back the chance of illness development and permit sufferers not requiring oxygen to get better from dwelling when applicable.”

Remdesivir was the primary antiviral for COVID-19 approved by the FDA. It was given to then-President Donald Trump when he was hospitalized with COVID-19 in October 2020.

Gilead launched the research findings in September.